Placing more resources toward and greater attention on its product Liprostin for peripheral arterial occlusive disease, Endovasc Inc. decided to stop funding preclinical research of a nicotine receptor agonist (NRA) in coronary artery disease. (BioWorld Today)

Raising $65.2 million in its largest financing to date, Gemin X Biotechnologies Inc. plans to advance its lead oncology candidate through Phase II studies. (BioWorld Today)

Signing its fourth major drug discovery alliance, Lexicon Genetics Inc. formed a $72.5 million collaboration with NV Organon to find five drug candidates for inflammatory disease. (BioWorld Today)